4.5 (544) In stock
Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling drug by annual revenue in 2023, earning $22.2 billion
Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling drug by annual revenue in 2023, earning $22.2 billion by 2025, according to new research by GlobalData.Article by pharmaphorum.comThe data forecasts th
Technologies in 3D-printing - Pharma Excipients
Top drugs and companies by sales in 2017
Top 15 Pharmaceutical Companies in the World in 2023 by Sales
Five companies personalizing treatments with 3D printed drugs
Leading-Drugs-Under-Fire-2015
Injecting Innovation into Drug Packaging
Top 10 Pharmaceutical Companies 2018 - pharma excipients
Biggest blockbuster drugs of 2020 : Drug sales and beyond – Pharmaceutical Marketing and Strategies for Today
Prescription Drugs Market Size, Share, Trends, Opportunities Analysis Forecast Report by 2030
The Most Innovative Excipients Manufacturers and Suppliers, PharmaCentral
Pharmaceutical Excipients Market Size, Share, Trends and Revenue Forecast [Latest]
